Navigation Links
A redeeming role for a common virus
Date:10/20/2010

Washington, DC A common virus that can cause coughing and mild diarrhea appears to have a major redemptive quality: the ability to kill cancer. Harnessing that power, researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center, are conducting a clinical trial to see if the virus can target and kill certain tumor types.

By the age of five, most people have been exposed to the virus, called reovirus. For some, it can trigger brief episodes of coughing or diarrhea while many other don't develop any symptoms. The body simply overpowers the virus. But what scientists have discovered is that the virus grows like gangbusters inside tumor cells with a specific malfunction that leads to tumor growth. That finding led researchers to ask: Is it possible to use the virus as a treatment?

At Lombardi, researchers are collaborating with other institutions to look for an answer by conducting a phase II clinical trial for people with advanced or recurrent non-small cell lung cancer with a specific tumor profile.

"With reovirus, we're able to accentuate the positive and attenuate the negative," says the study's lead investigator at Lombardi, Deepa Subramaniam, MD, interim-chief of the Thoracic Medical Oncology Program. In other words, researchers have genetically altered the virus so that it won't replicate in a healthy cell (attenuated), which is what makes a person sick. "What's left is a virus in search of a host, and reovirus loves the environment inside a specific kind of cancer cell," explains Subramaniam.

That specific kind of cancer cell is one with malfunctioning machinery called KRAS or EGFR mutation.

"These mutations leave the cancer vulnerable to a viral take-over. Once it's in, the reovirus exploits the cell's machinery to drive its own replication. As a result, the cell is filled with virus particles causing it to literally explode."

Volunteers in the clinical trial will receive reovirus (REOLYSIN) in addition to paclitaxel and carboplatin. The physicians will watch to see if the cancer shrinks while also seeing if this combination of drugs causes serious side effects.

"This is a subset of cancer where we haven't had many successes in terms of finding drugs that extend life after diagnosis," says Subramaniam. "This trial represents an attempt to seek and destroy cancer by choosing a treatment based on specific tumor characteristics. Preliminary data from the study should come quickly."

Researchers are also studying the effect of reovirus in other cancer types.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Adapting to clogged airways makes common pathogen resist powerful drugs
2. A common cholesterol drug fights cataracts, too
3. U.S. National Guard Connects Nationwide with Desktop Alert's Command and Control Mass Notification Systems and Common Alerting Protocol (CAP)
4. US21, Inc. is Granted a Wholesale Distributor Permit from the Commonwealth of Virginia Board of Pharmacy
5. New therapeutic target for most common solid cancer in childhood?
6. Migraine More Common in Women with MS
7. Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis
8. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
9. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
10. Common osteoporosis drugs are associated with a decrease in risk of breast cancer
11. Commonwealth Leverage Group and Helium Interactive Form HIE Go-To-Market Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... the company will provide alerting technology to Central Illinois Health Information Exchange ... million in federal funds as the sole sub-recipient participating with the Illinois ...
(Date:12/5/2016)... ... December 05, 2016 , ... BSI and Brenntag Canada have been appointed by ... distribution of their natural fruits and beverage colorants effective November 1, 2016. ... to our Life Sciences product portfolio,” said Steve Brauer, President of Brenntag Specialties, Inc. ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... U.S. Apple ... nationwide as part of the second annual Apples for Education: Buy an Apple, ... food bank providing healthy food for students to take home to their families; solar ...
(Date:12/5/2016)... ... December 05, 2016 , ... Florida Hospital has named ... Florida Region. McGuinness brings experience in executive leadership and clinical practice, as well ... , In her new role, that officially begins December 12, 2016, she will ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Life Will Never Be The ... family and friends. “Life Will Never Be The Same” is the creation of published ... writing children's books and holds a degree in Christian religion and philosophy from Judson ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Health and Gateway Health proudly announce a dynamic collaboration that ... plan members with specific high risk needs. In ... group of consumers, Wellbridge combines technology and population expertise with ... members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... , Dec. 5, 2016  New research ... ) Research Institute and the U.S. Department of ... Secretary for Preparedness and Response (ASPR), published online ... that automated pharmacy notifications encourage patients with chronic ... natural disaster. The study also affirms that public-private ...
(Date:12/5/2016)...  BD (Becton, Dickinson and Company) (NYSE: ... demonstrate an enhanced technology platform designed with the ability ... leading Pyxis™ and Alaris™ systems, at this year,s ... being held in Las Vegas ... show that approximately 68 percent of medication errors occur ...
Breaking Medicine Technology: